Floatz logo

Optison

Pelvic Neoplasms

St. Jude Children's Research HospitalPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pelvic Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Eli Lilly and Company
Phase 3BB
Inno-206
Eli Lilly and Company
Phase 3BB
TENIFATECAN
Achieve Life Sciences
Phase 1CC

Same molecule, other indications

Optison is also rated in:

atrial fibrillationDormant
BB
Indicative ·
65 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
Abdominal NeoplasmsDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →